Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.
2.

The "urban myth" of the association between neurological disorders and vaccinations.

Gasparini R, Panatto D, Lai PL, Amicizia D.

J Prev Med Hyg. 2015 Jun 10;56(1):E1-8.

3.

Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination.

Le Houézec D.

Immunol Res. 2014 Dec;60(2-3):219-25. doi: 10.1007/s12026-014-8574-4.

4.

Twenty years of universal vaccination against hepatitis B in Italy: achievements and challenges.

Romanò L, Paladini S, Zanetti AR.

J Public Health Res. 2012 Apr 30;1(2):126-9. doi: 10.4081/jphr.2012.e18. Review.

5.

Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Oreja-Guevara C, Wiendl H, Kieseier BC, Airas L; NeuroNet Study Group..

Ther Adv Neurol Disord. 2014 Mar;7(2):137-49. doi: 10.1177/1756285613501575. Review.

6.

A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis.

Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VA, Vittori D, Fornasiero A, Buscarinu MC; International Multiple Sclerosis Genetics Consortium.; Wellcome Trust Case Control Consortium,2., Romano S, Salvetti M, Ristori G.

PLoS One. 2013 May 16;8(5):e63300. doi: 10.1371/journal.pone.0063300.

7.

Vaccinations in patients with immune-mediated inflammatory diseases.

Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, Masson P, De Keyser F.

Rheumatology (Oxford). 2010 Oct;49(10):1815-27. doi: 10.1093/rheumatology/keq183. Review.

8.

Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk.

Simon KC, van der Mei IA, Munger KL, Ponsonby A, Dickinson J, Dwyer T, Sundström P, Ascherio A.

Neurology. 2010 Apr 27;74(17):1365-71. doi: 10.1212/WNL.0b013e3181dad57e.

9.

Determinants of parents' reticence toward vaccination in urban areas in Benin (West Africa).

Fourn L, Haddad S, Fournier P, Gansey R.

BMC Int Health Hum Rights. 2009 Oct 14;9 Suppl 1:S14. doi: 10.1186/1472-698X-9-S1-S14.

10.

Vaccination safety update.

Schneeweiss B, Pfleiderer M, Keller-Stanislawski B.

Dtsch Arztebl Int. 2008 Aug;105(34-35):590-5. doi: 10.3238/arztebl.2008.0590.

11.

Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis.

Tai AK, O'Reilly EJ, Alroy KA, Simon KC, Munger KL, Huber BT, Ascherio A.

Mult Scler. 2008 Nov;14(9):1175-80. doi: 10.1177/1352458508094641.

12.

Future prospectives for the management of chronic hepatitis B.

Leemans W, Janssen HL, de Man R.

World J Gastroenterol. 2007 May 14;13(18):2554-67. Review.

13.

Awareness of vaccination status and its predictors among working people in Switzerland.

Lee CY, Naguel C, Gyurech D, Duvoisin N, Schilling J.

BMC Public Health. 2003 Jun 2;3:18.

14.

Vaccination and rheumatoid arthritis.

Sibilia J, Maillefert JF.

Ann Rheum Dis. 2002 Jul;61(7):575-6. No abstract available.

15.

Active immunization in the United States: developments over the past decade.

Dennehy PH.

Clin Microbiol Rev. 2001 Oct;14(4):872-908, table of contents. Review.

Supplemental Content

Support Center